Lynne Murray currently holds the position of VP, Head of UK Research, Site Head for Oxford at Gilead Sciences. Prior to this, Lynne served as the Chief Scientific Officer at MiroBio Ltd, SVP R&D at an undisclosed company, and was part of the Respiratory, Inflammation, Autoimmunity (RIA) IMED Biotech unit at AstraZeneca. With a strong background in research and strategy, Lynne has also held roles at MedImmune, Pulmonary Research Group, Promedior, Inc., and Centocor. Lynne completed a PhD in Immunology and Pathology at Imperial College London, followed by a PostDoc in Pulmonary and Critical Care Medicine at UCLA. Additionally, Lynne holds a BSc in Pharmacology from King's College London and an MBA from the University of Cambridge.
December, 2022 - present